54.78MMarket Cap
LossP/E TTM
Key Figures
1.540Open
1.640High
50.18KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.15%Turnover Ratio
1.580Prev. Close
1.500Low
65.65KTurnover
LossP/E Static
0.68P/B
0.00%Div Yield TTM
-37.14%ROA
9.50052wk High
1.50Volume Ratio
-13.38MNet Profit
33.40MShares
-7.1350EPS TTM
1.71Beta
-109.66%ROE
1.28052wk Low
8.86%Amplitude
--Gross Margin
54.78MMarket Cap
2.68Reward/Risk
5.40%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Dogwood Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 159 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dogwood Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Dogwood Therapeutics Inc Highlights
StrengthsRisks
Dogwood Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Dogwood Therapeutics Inc
DWTX
2
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Dogwood Therapeutics Inc Info
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Ticker SymbolDWTX
CompanyDogwood Therapeutics Inc
CEODuncan (Gregory Scott)
Websitehttps://dwtx.com/
Shareholders
FAQs
What is the current price of Dogwood Therapeutics Inc (DWTX)?
The current price of Dogwood Therapeutics Inc (DWTX) is 1.64.
What is the symbol of Dogwood Therapeutics Inc?
The ticker symbol of Dogwood Therapeutics Inc is DWTX.
What is the 52-week high of Dogwood Therapeutics Inc?
The 52-week high of Dogwood Therapeutics Inc is 9.50.
What is the 52-week low of Dogwood Therapeutics Inc?
The 52-week low of Dogwood Therapeutics Inc is 1.28.
What is the market capitalization of Dogwood Therapeutics Inc?
The market capitalization of Dogwood Therapeutics Inc is 48.78M.
Is Dogwood Therapeutics Inc (DWTX) currently rated as Buy, Hold, or Sell?
According to analysts, Dogwood Therapeutics Inc (DWTX) has an overall rating of Buy, with a price target of 13.50.
What is the Earnings Per Share (EPS TTM) of Dogwood Therapeutics Inc (DWTX)?
The Earnings Per Share (EPS TTM) of Dogwood Therapeutics Inc (DWTX) is -7.13.
